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Aims Hyperkalaemia and hypokalaemia are common in heart failure and associated with worse outcomes. However, the
optimal potassium range is unknown. We sought to determine the optimal range of potassium in patients with heart
failure and reduced ejection fraction (< 40%) by exploring the relationship between baseline potassium level and
short- and long-term outcomes using the Swedish Heart Failure Registry from 1 January 2006 to 31 December
2012.
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Methods
and results
We assessed the association between baseline potassium level and all-cause mortality at 30 days, 12 months, and
maximal follow-up, in uni- and multivariable stratified and restricted cubic spline Cox regressions. Of 13 015 patients,
93.3% had potassium 3.5–5.0 mmol/L, 3.7% had potassium <3.5 mmol/L, and 3.0% had potassium >5.0 mmol/L.
Potassium <3.5 mmol/L and >5.0 mmol/L were more common with lower estimated glomerular filtration rate and
heart failure of longer duration and greater severity. The potassium level associated with the lowest hazard risk for
mortality at 30 days, 12 months, and maximal follow-up was 4.2 mmol/L, and there was a steep increase in risk with
both higher and lower potassium levels. In adjusted strata analyses, lower potassium was independently associated
with all-cause mortality at 12 months and maximal follow-up, while higher potassium levels only increased risk at
30 days.
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Conclusion In this nationwide registry, the relationship between potassium and mortality was U-shaped, with an optimal potassium
value of 4.2 mmol/L. After multivariable adjustment, hypokalaemia was associated with increased long-term mortality
but hyperkalaemia was associated with increased short-term mortality.
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Introduction
Heart failure is estimated to affect up to 40 million people
worldwide and is associated with high morbidity and mortality.1–3
Because of the pathophysiology of the syndrome, recommended
treatments and concomitant comorbidities, electrolyte abnormali-
ties of hyper- and hypokalaemia are common, often contributing to
morbidity and mortality.4–6 A normal population-reference range
for serum potassium is established as 3.5–5.0 mmol/L.7,8 In hyper-
tension, after myocardial infarction complicated by heart failure,
and in chronic heart failure, potassium values outside the normal
range but also at the lower and higher ends of the normal range are
associated with increased short-term mortality.9–11 Similar findings
have been shown in advanced chronic kidney disease.12,13 Whether
a narrower range of potassium values impacts longer term out-
comes in chronic heart failure warrants further investigation.
We used the Swedish Heart Failure Registry (SwedeHF; www
.SwedeHF.se) to assess patients with heart failure with reduced
ejection fraction (HFrEF) and investigate (i) the distribution of
potassium values and its association with clinical characteristics,
and (ii) the association between baseline potassium and short- and
long-term all-cause mortality and incident hyperkalaemia.
Methods
Data sources
We used SwedeHF, a nationwide registry funded by the Swedish Fed-
eral Government through the Swedish Association of Local Authori-
ties and Regions (www.SKL.se), which started as a pilot in 2000 and
was introduced nationwide in 2003. The registry has been described
previously.14 Patients are eligible based on clinician-determined heart
failure, and data are entered into the registry by local clinicians at the
time of hospital discharge or an outpatient clinic visit. Laboratory data
and baseline prescription drug use at the time of first entry into the
registry are included. Ejection fraction (EF) is included in the registry,
though date of echocardiograms has a high percentage of missingness.
SwedeHF can be linked with several national government-sponsored
health and statistical registries through the unique identification num-
ber that is given to every permanent resident of Sweden. For this study,
the Population Registry provided vital status and date of death; the
National Patient Registry provided information on baseline comorbidi-
ties and on the outcomes of hyperkalaemia. Statistics Sweden provided
socioeconomic data.
Study population
We identified SwedeHF Registry participants with an index visit
between 1 January 2006 (when the Prescribed Drug Registry was intro-
duced) and 31 December 2012. We did not include patients who died
during the index hospitalization. Patients with HFrEF (EF < 40%) were
included in this study, whereas patients with EF ≥40% or missing EF
information were excluded (online supplementary Figure S1). We also
excluded patients with missing data for New York Heart Association
(NYHA) class, potassium level, angiotensin-converting enzyme (ACE)
inhibitor or angiotensin II receptor blocker (ARB) use, or mineralo-
corticoid receptor antagonist (MRA) use. We excluded patients in



















































































.. (eGFR), patients on dialysis at the time of registration, and patients who
died during the index hospitalization.
Baseline study variables
The study population was divided into groups based on base-
line potassium level (hypokalaemia <3.5 mmol/L, normokalaemia
3.5–5.0 mmol/L, mild hyperkalaemia 5.1–5.5 mmol/L, and hyper-
kalaemia >5.5 mmol/L), measured either from serum or plasma, as
some centres use serum potassium and some use plasma potassium.
All baseline data were at the index date, which was at hospital
discharge or outpatient clinic visit. Comorbidities were reported in
SwedeHF and/or defined by International Statistical Classification of
Diseases, Tenth Revision (ICD-10) codes, and cause-specific outcomes
were defined by ICD-10 codes (online supplementary Table S1). Renal
function was calculated using the Chronic Kidney Disease Epidemi-
ology Collaboration equation.15 Baseline prescription drug use was
recorded as per protocol in SwedeHF.
Outcomes
The primary outcome was all-cause mortality at 30 days, 12 months,
and maximal follow-up. Mortality was obtained from the Population
Registry with virtually no loss to follow-up. Secondary outcomes
included hyperkalaemia, which were obtained from the Patient Reg-
istry, and defined by inpatient or outpatient visits with the correspond-
ing ICD-10 codes in any diagnosis position.
Statistical analysis
Baseline characteristics were summarized by medians with interquar-
tile ranges for continuous variables and percentages for categorical
variables. Variables were compared using the chi-square test for cat-
egorical variables and the Kruskal–Wallis test for continuous vari-
ables. We produced histograms of potassium values, and scatterplots
of potassium values by renal function, noting the cubic smoothing spline
and the median values.15
We used the Kaplan–Meier method to estimate all-cause mortal-
ity at 30 days, 12 months, and 5 years, stratified by baseline potas-
sium categories. In a secondary analysis, we also used Cox propor-
tional hazard regression models to examine the association between
four categorical baseline potassium levels (<3.5, 3.5–5.0, 5.1–5.5, and
>5.5 mmol/L) and mortality up to 30 days, 12 months, and maximal
follow-up because these potassium categories are commonly used in
trials examining serum potassium.16–18 We also used Cox proportional
hazard regression models to assess the relationship between baseline
potassium levels as a continuous variable, modelled with a restricted
cubic spline with four degrees of freedom, and the outcomes of 30-day,
12-month, and maximal follow-up mortality and hyperkalaemia and
plotted the functional form. The restricted cubic spline curves show
the function relating potassium to the respective outcomes where the
mean of baseline potassium across all patients is set to the reference
value (hazard ratio = 1). Variables adjusted for in the model are noted
in Table 1, including patient characteristics (age, gender, heart failure
duration, NYHA class, EF), medical history (presence of defibrillator,
pacemaker, or cardiac resynchronization therapy; history of myocardial
infarction, revascularization, peripheral artery disease, stroke, atrial
fibrillation or flutter, severe bleeding, hypertension, diabetes, malig-
nant cancer, alcoholism, liver disease, lung disease, musculoskeletal
problems, mental health problems), baseline vital signs (systolic blood
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Table 1 Baseline characteristics






K+ > 5.5 mmol/L
(n = 63)
P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Patient characteristics
Age, yearsa,b 0 75 (65–83) 72 (63–80) 73 (65–80) 72 (65–78) <0.001
Male sexa 0 61% 74% 78% 73% <0.001
BMI, kg/m2b 50 26 (22–30) 26 (23–30) 25 (22–29) 25 (23–27) 0.02
Duration of HFa 0 <0.001
<6 months 43% 49% 35% 38%
≥6 months 57% 51% 65% 62%
NYHA classa 0 <0.001
I 5% 9% 4% 6%
II 34% 45% 37% 33%
III 50% 41% 47% 51%
IV 11% 4% 11% 10%
Ejection fractiona 0 0.28
<30% 57% 53% 54% 54%
30–39% 43% 47% 46% 46%
Baseline assessments
Systolic BP, mmHga,b 1 125 (110–140) 120 (110–140) 120 (105–130) 110 (100–126) <0.001
Diastolic BP, mmHgb 1 72 (65–82) 70 (65–80) 70 (60–80) 70 (60–75) <0.001




0 61 (43–80) 65 (47–83) 46 (33–66) 37 (27–50) <0.001
Haemoglobin, g/La,b 0 131 (118–142) 136 (124–147) 132 (118–147) 124 (110–140) <0.001
NT-proBNP, pg/mL 55 4932 (1979–9759) 2720 (1,200–5988) 3975 (1844–7606) 5818 (2309–8756) <0.001
Medical history
Anaemia 0 37% 28% 40% 52% <0.001
Implantable
cardioverter-defibrillatora
0 5% 6% 6% 3% 0.39
Cardiac resynchronization
therapya
0 4% 6% 8% 6% 0.06
Pacemakera 0 9% 7% 10% 10% 0.22
Myocardial infarctiona 0 44% 42% 45% 51% 0.23
Revascularizeda 0 31% 31% 30% 37% 0.75
Peripheral artery diseasea 0 13% 10% 12% 13% 0.04
Stroke/transient ischemic attacka 0 17% 14% 18% 19% 0.05
Atrial fibrillation/fluttera 0 52% 47% 48% 57% 0.09
Any severe bleeda 0 25% 17% 26% 22% <0.001
Hypertensiona 0 55% 48% 53% 46% 0.01
Diabetesa 0 28% 25% 36% 32% <0.001
Malignant cancera (past 3 years) 0 15% 12% 13% 8% 0.22
Alcoholisma 0 6% 5% 7% 8% 0.09
Liver diseasea 0 2% 2% 1% 3% 0.63
Lung diseasea 0 29% 24% 25% 29% 0.06
Musculoskeletal problemsa (past
3 years)
0 28% 26% 26% 16% 0.18
Mental health problemsa (past
3 years)
0 17% 12% 13% 17% 0.01
Prior hyperkalaemia 0 2% 1% 5% 6% <0.001
Prior hypokalaemia 0 5% 1% 1% 2% <0.001
Medications
ACE inhibitor/ARBa 0 86% 93% 92% 87% <0.001
New prescription 21% 13% 6% 10%
Old prescription 65% 80% 86% 78%
© 2020 European Society of Cardiology
Association between potassium level and outcomes 1393
Table 1 (Continued)






K+ > 5.5 mmol/L
(n = 63)
P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
MRAa 0 39% 34% 41% 40% 0.01
New prescription 22% 10% 7% 3%
Old prescription 17% 24% 34% 37%
Beta-blockera 0 93% 92% 93% 89% 0.55
Statina 0 47% 52% 49% 48% 0.09
Diuretic (loop or thiazide)a 0 92% 77% 86% 83% <0.001
Digoxina 0 19% 17% 14% 11% 0.28
Nitratesa 0 16% 14% 17% 13% 0.16
Platelet inhibitora 0 52% 50% 48% 59% 0.46
Oral anticoagulanta 0 37% 42% 42% 41% 0.11
ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; BMI, body mass index; BP, blood pressure; HF, heart failure; MRA, mineralocorticoid receptor
antagonist; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association.
Patients with missing values for potassium or estimated glomerular filtration rate; ACE inhibitor, ARB, or MRA use; or ejection fraction were excluded. For remaining variables,
the % missing is listed.
aVariable included in multivariable models.
bData expressed as median (Q1–Q3).
pressure, heart rate), baseline laboratory values (glomerular filtration
rate, haemoglobin), and baseline medication use (ACE inhibitor/ARB,
MRA, beta-blocker, statin, diuretic, digoxin, nitrates, platelet inhibitor,
oral anticoagulant). Adjustment variables were chosen based on clini-
cal relevance and their potential role in associating with hypokalaemia
or hyperkalaemia and/or outcomes. Given the very large sample size
and large number of events, we did not employ any statistical variable
selection procedure. After the inclusion and exclusion criteria were
applied, 33 of the 35 variables included in the multivariable models had
0% missing data and two variables had 1% missing data.
We used R version 3.1.3 (R Foundation for Statistical Computing,
Vienna, Austria) for all analyses.
Ethics
Establishment of the SwedeHF Registry and this analysis with linking
of the above registries was approved by a multi-site ethics committee.
Individual patient consent was not required, but patients were informed
of entry into national registries and allowed to opt out.
Results
Distribution of and associations
with potassium levels
Of the 13 015 patients included in this analysis, the majority of
patients had potassium levels within the normal reference range
(K+ 3.5–5.0 mmol/L, 93.3%) (Figure 1A). Patients with eGFR >60
mL/min/1.73 m2 had potassium levels closely centred in the normal
range. Across lower eGFR status, higher and lower potassium
values were more common (Figure 1B).
Overall, the mean age was 71 years and 27% were women
(Table 1). Patients in the hypokalaemia (K+ <3.5 mmol/L) group
were older and more likely female than those with normokalaemia
or hyperkalaemia. Patients with normokalaemia were more likely



















































.. no significant difference between the groups for frequency of EF
30–39% vs. <30%.
A majority of patients in all groups were on an ACE inhibitor or
ARB (86% with K+ <3.5 mmol/L, 93% with K+ 3.5–5.0 mmol/L,
92% with K+ 5.1–5.5 mmol/L, and 87% with K+ >5.5 mmol/L),
while a lower percentage of patients in each group were on MRA
therapy (39% with K+ <3.5 mmol/L, 34% with K+ 3.5–5.0 mmol/L,
41% with K+ 5.1–5.5 mmol/L, and 40% with K+ >5.5 mmol/L).
Association between baseline potassium
level and outcomes – event rates
The median follow-up was 2.0 years overall. At 30 days, 12
months and 5 years, crude survival with normal potassium
(3.5–5.0 mmol/L) was better compared to those with hyper-
kalaemia and hypokalaemia (Figure 2). In exploratory analyses
further stratifying by narrower categorical potassium levels,
patients with K+ ≥6.0 mmol/L had the lowest survival compared
to the other groups at all time points (Figure 3). At 12 months,
survival for those with K+ 4.0–4.4 mmol/L and those with K+
4.5–4.9 mmol/L was higher than survival for all other groups. At
5 years, patients with K+ 4.0–4.4 mmol/L had higher survival than
all other groups.
Association between baseline potassium
level and mortality – stratified and spline
Cox regressions
In unadjusted spline analyses, there was a sharp U-shaped rela-
tionship between potassium level and mortality risk at 30 days, 12
months and maximal follow-up; the lowest hazard ratio for mor-
tality was at K+ 4.2 mmol/L, with a steep increase in risk with both
higher and lower potassium levels (Figure 4A–C). In unadjusted
strata analyses, patients with K+ <3.5 mmol/L had an increased
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Figure 1 Distribution of baseline potassium values of the study population. (A) Overall distribution of baseline potassium. (B) Distribution
of baseline potassium by estimated glomerular filtration rate. Note: blue line represents median potassium and estimated glomerular filtration
rate values; red line represents cubic smoothing spline. CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration.
Figure 2 Survival rates from Kaplan–Meier estimates among the study population by baseline potassium level. Thirty-day (A), 12-month (B)
and 5-year survival (C) by four groups: K+ <3.5 mmol/L, K+ 3.5–5.0 mmol/L, K+ 5.1–5.5 mmol/L, and K+ >5.5 mmol/L.
risk of short- and long-term mortality compared with patients with
K+ 3.5–5.0 mmol/L (online supplementary Table S2). Patients with
K+ >5.0 mmol/L also had an increased risk of short- and long-term
mortality compared to those with normokalaemia.
In adjusted spline analyses, the potassium level associated
with the lowest hazard ratio for mortality at 30 days was
4.1 mmol/L, and at 12 months and maximal follow-up was
4.2 mmol/L (Figure 4D–F). Visually, at all time periods, the risk of
mortality increases with lower potassium levels. However, higher
potassium levels were associated with increased risk of mortality
only at 30 days, not at longer follow-up intervals. In the secondary
adjusted strata analyses (adjusted for variables listed in Table 1),
K+ <3.5 was associated with increased risk of mortality at 12
months and maximal follow-up, but not at 30 days. K+ 5.1–5.5






















. 30 days, 12 months, or maximal follow-up. At 30 days, K+ >5.5 was
associated with increased adjusted risk of mortality (Figure 4D-F
and online supplementary Table S2).
Association between baseline potassium
level and incident hyperkalaemia during
follow-up
In univariate analyses, higher baseline potassium level was visu-
ally associated with increased risk of hyperkalaemia at 30 days, 12
months, and maximal follow-up; notably, lower baseline potassium
level was also associated with increased risk of hyperkalaemia at all
time points (online supplementary Figure S2). In multivariate anal-
yses, both lower and higher potassium at baseline were associated
© 2020 European Society of Cardiology
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Figure 3 Survival rates from Kaplan–Meier estimates among the study population by baseline potassium level. Thirty-day (A), 12-month (B)
and 5-year survival (C) by seven groups: K+ <3.5 mmol/L, K+ 3.5–3.9 mmol/L, K+ 4.0–4.4 mmol/L, K+ 4.5–4.9 mmol/L, K+ 5.0–5.4 mmol/L,
K+ 5.5–5.9 mmol/L, and K+ ≥6.0 mmol/L.
Figure 4 Risk of mortality by baseline potassium level. (A–C) Unadjusted risk of 30-day (A) and 12-month mortality (B) and unadjusted risk
of mortality at maximal follow-up (C): K+ 4.2 mmol/L was associated with the lowest risk of mortality. (D) Adjusted risk of 30-day mortality:
K+ 4.1 mmol/L was associated with the lowest adjusted risk of 30-day mortality. (E) Adjusted risk of 12-month mortality and (F) adjusted risk
of mortality at maximal follow-up: K+ 4.2 mmol/L was associated with the lowest adjusted risk of mortality.
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with increased risk of hyperkalaemia after adjusting for baseline
characteristics (online supplementary Figure S3).
Discussion
In this comprehensive analysis examining potassium levels in
patients with HFrEF in a large population-based registry, we
showed that (i) most patients had a potassium level in the his-
torically used normal reference range of 3.5–5.0 mmol/L; (ii) the
relationship between potassium level and short- and long-term
mortality was U-shaped, with an optimal potassium range much
narrower than the range considered normal in routine clinical prac-
tice; but (iii) after covariate adjustment, hypokalaemia remained
associated with increased long-term mortality at all time ranges,
whereas hyperkalaemia remained associated only with increased
short-term but not long-term mortality; and (iv) the risk of inci-
dent hyperkalaemia was potentially associated with both higher and
lower potassium levels at baseline.
Optimal potassium levels and mortality
This study confirms what prior analyses from clinical trials and reg-
istries have shown, that hyperkalaemia and hypokalaemia are both
associated with increased risk of mortality in patients with heart
failure.11,16,18–20 While some prior studies examined outcomes for
potassium values above and below a ‘normal range,’ we sought to
identify a more ‘optimal range’ for potassium in heart failure. Our
results showed a narrow U-shaped relationship between potas-
sium and mortality with K+ 4.2 mmol/L having the lowest risk of
mortality, with worse short- and long-term survival with potas-
sium above and below this value, confirming the results of prior
analyses with respect to short-term mortality,11 and extending, for
the first time, these findings to longer-term mortality. In multivari-
able analyses, K+ 4.1–4.2 mmol/L was associated with the lowest
mortality for short- and long-term follow-up. Our findings sug-
gest that for patients with HFrEF, clinicians should be aware of
the increased risk outside a much more narrow range of potas-
sium values than the traditionally defined normal potassium levels
of 3.5–5.0 mmol/L. This is particularly relevant in light of data sug-
gesting that in clinical practice, potassium levels are not monitored
according to guidelines.21,22
Hypokalaemia and outcomes
Hypokalaemia was associated with mortality in short- and
long-term follow-up. Hypokalaemia may be a risk marker for high
or variable diuretic dosing and thus more severe heart failure,
congestion, chronic kidney disease, and cardiorenal syndrome.
Hypokalaemia is worsened by diuretic therapy and patients with
hypokalaemia may be more resistant to diuretic therapy in acute
decompensated heart failure.23,24 Indeed, in this study, baseline
hypokalaemia was visually associated with an increased risk of
hyperkalaemia, consistent with renal dysfunction and electrolyte
disturbances that are more difficult to manage or predict. This
study demonstrates that patients with abnormal potassium, either
low or high levels, are more likely to present with metabolic



















































































.. Furthermore, after adjustment for eGFR and other covariates,
hypokalaemia remained associated with increased long-term mor-
tality suggesting that in addition to a risk marker, it may also repre-
sent a risk factor. This association may be potentially mediated via
increased risk of ventricular arrhythmias and sudden cardiac death.
In addition, activation of the renin–angiotensin–aldosterone sys-
tem results in hypokalaemia.6 The results of the current study,
taken together with prior studies, reinforce the importance of
avoiding hypokalaemia in patients with heart failure.
Hyperkalaemia and outcomes
While hyperkalaemia was associated with increased short and
long-term mortality in univariable analyses, after adjustment, hyper-
kalaemia was associated only with increased mortality at 30 days,
not at 12 months or maximal follow-up. Thus, hyperkalaemia was a
risk factor in the short term, possibly by contributing to metabolic
derangements and arrhythmias. In contrast, over time it was merely
a risk marker for other risk factors. Prior work shows that pre-
dictors of hyperkalaemia include renal dysfunction and diabetes,
which, together with greater severity of heart failure, cardiorenal
syndrome and diuretic resistance, increase the risk of mortality in
patients with heart failure.16,17,25
Interestingly, in this study, MRA use was greater in patients
with hypokalaemia – suggesting MRAs may be used in part to
increase potassium levels – and hyperkalaemia, which may be a
consequence of MRA therapy. Indeed, ACE inhibitors, ARBs, and
MRAs are common causes of hyperkalaemia and patients with
hyperkalaemia are more likely to be on these drugs, though prior
work shows that mortality benefit of these drugs remains, even
with hyperkalaemia.16,26–29 Thus, discontinuation of these life-saving
drugs may play a role in increasing long-term mortality in these
high-risk patients.28 While the actual direct risk of hyperkalaemia
may be overestimated, the perceived risk leads to avoidance, dose
reduction or discontinuation of these drugs, which may play a role
in long-term mortality.30–32
Future directions
This study adds to previous studies which examined short-term
outcomes in patients with hypertension, with heart failure after
myocardial infarction, and with chronic heart failure supporting an
‘optimal’ potassium range that is narrower and on the higher end of
what is considered a ‘normal’ range. Krogager and colleagues found
that for patients with acute heart failure after myocardial infarc-
tion, the risk of death at 90 days was lowest in patients with serum
K+ 3.9–4.5 mmol/L.10 In advanced chronic kidney disease, 180-day
mortality was lowest with plasma K+ 4.2–4.3 mmol/L.13 Similarly,
in patients with chronic heart failure, serum potassium levels out-
side the 4.2–4.7 mmol/L range were associated with increased
short-term risk of death.11 Our current study shows compara-
ble findings in patients with chronic heart failure with longer term
outcomes. Furthermore, our study includes comprehensive adjust-
ment for clinical laboratory and medication variables, with novel
results that suggest that hyperkalaemia is primarily a risk marker
rather than a risk factor.
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However, despite these findings, it is unknown if the correction
of potassium to an optimal level can attenuate these risks. For
hyperkalaemia in particular, our study highlights the importance
of recognizing underlying factors as well as under-utilization
of renin–angiotensin–aldosterone system inhibitors, particu-
larly MRAs, as potentially the main drivers of worse long-term
outcomes. Future studies using potassium supplements for
hypokalaemia or potassium binders for hyperkalaemia are war-
ranted to determine the effect on short- and long-term outcomes
and whether they can contribute to optimal use of life-saving heart
failure medications.
Limitations
Our study should be taken in the context of some limitations. First,
the study population was derived from the SwedeHF Registry,
so the results may not be generalizable to other populations or
other geographic regions. Further, the patient population is from
2006–2012, so the results may not be generalizable to current
patients. The most notable difference between that era and the
current one is the introduction of sacubitril/valsartan for patients
with HFrEF, which was approved in 2015. Second, participation
in the registry is voluntary, so while most health care facilities
report to the registry, the registry does not capture all care
throughout Sweden. In addition, we were limited by data available
in the registry. Due to the large scale of this registry, some data
were missing. We excluded patients with relevant missing data
including patients with missing NYHA class, potassium level, and
renal function. Further, we did not examine mode of death, which
limits our understanding of the relationship between dyskalaemia
and outcomes. Third, while most centres in Sweden currently
measure potassium in plasma, some of these centres previously or
in addition measured potassium in serum and the SwedeHF Reg-
istry database does not differentiate the source of the laboratory
value.33 The mixture of serum and plasma values in this analysis
may impact the accuracy of the exact potassium value with the
lowest risk, the results still strongly support our main message that
the optimal potassium range is narrower than previously described.
Fourth, as with all retrospective observational analyses, there is a
possibility of residual unmeasured confounders. Fifth, despite the
large sample size, at lower and higher potassium, the confidence
intervals were wide and interpretations at the extremes of potas-
sium should be made with caution. In addition, potassium level
often fluctuates based on diet, medication, or change in renal func-
tion, so there are limitations inherent in using a single potassium
value to examine associations with long-term outcomes. Finally,
although the spline analyses provide a means to model non-linear
risk relationships, the position of the knots may influence both the
shape of the curve and the optimal potassium level.
Conclusions
In this nationwide registry, the relationship between potassium
level and mortality was U-shaped, with an optimal potassium value



















































































.. associated with increased long-term mortality, while hyperkalaemia
was associated only with increased short-term mortality. This
adds to the literature that for select patients, clinicians should
be targeting a narrower goal potassium range than what has
traditionally been considered within the normal range.
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